{
    "clinical_study": {
        "@rank": "13212", 
        "arm_group": [
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Injection of 1 mL alirocumab SAR236553 (REGN727) Dose 1 every 2 weeks through subcutaneous administration in the abdomen.\nalirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).\nAtorvastatin will be administered once daily in the evening at a stable dose as background therapy."
            }, 
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Injection of 1 mL alirocumab SAR236553 (REGN727) Dose 2 every 2 weeks through subcutaneous administration in the abdomen.\nAtorvastatin will be administered once daily in the evening at a stable dose as background therapy."
            }, 
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Injection of 1 mL alirocumab SAR236553 (REGN727) Dose 3 every 2 weeks through subcutaneous administration in the abdomen.\nAtorvastatin will be administered once daily in the evening at a stable dose as background therapy."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Injection of 1 mL alirocumab SAR236553 (REGN727) matching placebo every 2 weeks through subcutaneous administration in the abdomen.\nAtorvastatin will be administered once daily in the evening at a stable dose as background therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate the effect of alirocumab SAR236553 (REGN727) on low-density lipoprotein\n      cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in\n      patients with LDL-C \u2265100 mg/dL (\u22652.59 mmol/L) on ongoing stable atorvastatin therapy.\n\n      Secondary Objectives:\n\n      To evaluate the effects of alirocumab SAR236553 (REGN727) on other lipid levels after 12\n      weeks of treatment in comparison with placebo.\n\n      To evaluate the safety and tolerability of alirocumab SAR236553 (REGN727).\n\n      To evaluate the development of anti-alirocumab SAR236553 (REGN727) antibodies.\n\n      To evaluate the pharmacokinetics of alirocumab SAR236553 (REGN727)."
        }, 
        "brief_title": "Efficacy and Safety Evaluation of Alirocumab SAR236553 (REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "detailed_description": {
            "textblock": "The duration of study participation will depend on the status of the patient at screening:\n      21 to 27 weeks including a screening period of 1 to 7 weeks, a double-blind treatment period\n      of 12 weeks, followed by an 8 week follow-up period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n        Patients with primary hypercholesterolemia treated with atorvastatin at stable dose of\n        5-20 mg for at least 6 weeks prior to screening and likely to have LDL-C \u2265100 mg/dL (\u22652.59\n        mmol/L) at the screening visit.\n\n        OR Patients with primary hypercholesterolemia who are receiving a lipid-lowering treatment\n        other than atorvastatin, or who are not at stable dose of atorvastatin 5-20 mg for at\n        least 6 weeks prior to screening and who are likely to have LDL-C \u2265100 mg/dL (\u22652.59\n        mmol/L) after the run-in period on atorvastatin therapy.\n\n        Exclusion criteria:\n\n          1. LDL-C <100 mg/dL (<2.59 mmol/L) at Week -1 (V1): At the first visit for patients who\n             are being treated with stable dose of atorvastatin 5-20 mg for at least 6 weeks prior\n             to screening period.\n\n             OR After the run-in period on atorvastatin (5-20 mg) for patients receiving a lipid\n             lowering treatment other than atorvastatin, or not at stable dose of atorvastatin\n             5-20 mg for at least 6 weeks prior to screening period.\n\n          2. Patients with type 1 diabetes\n\n          3. Patients with type 2 diabetes treated with insulin, or without, and considered poorly\n             controlled at screening.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812707", 
            "org_study_id": "DFI12361", 
            "secondary_id": "U1111-1134-4749"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "alirocumab SAR236553 (REGN727) Dose 1", 
                    "alirocumab SAR236553 (REGN727) Dose 3", 
                    "alirocumab SAR236553 (REGN727) Dose 2"
                ], 
                "description": "Pharmaceutical form:solution for injection Route of administration: subcutaneous", 
                "intervention_name": "alirocumab SAR236553 (REGN727)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Pharmaceutical form:solution for injection Route of administration: subcutaneous", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "alirocumab SAR236553 (REGN727) Dose 1", 
                    "alirocumab SAR236553 (REGN727) Dose 3", 
                    "Placebo", 
                    "alirocumab SAR236553 (REGN727) Dose 2"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "atorvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Koganei-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392004"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol \u2265100 mg/dL (\u22652.59 mmol/L) on Ongoing Stable Atorvastatin Therapy", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percent change in calculated low-density lipoprotein cholesterol (LDL-C)", 
            "safety_issue": "No", 
            "time_frame": "From baseline to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812707"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute change in calculated low-density lipoprotein cholesterol (LDL-C)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 12"
            }, 
            {
                "measure": "Percent and absolute changes in other lipid parameters", 
                "safety_issue": "No", 
                "time_frame": "At Week 12"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}